

# Tramcoat 40 mg film-coated tablets for dogs

Authorised

- Tramadol hydrochloride

## Product identification

**Medicine name:**

Tramcoat 40 mg film-coated tablets for dogs

---

**Active substance:**

Tramadol hydrochloride

---

**Target species:**

Dog

---

**Route of administration:**

Oral use

---

## Product details

**Active substance and strength:**

Tramadol hydrochloride  
40.00 milligram(s) / 1.00 Tablet

---

**Pharmaceutical form:**

Film-coated tablet

---

**Withdrawal period by route of administration:****Oral use:**

- 

**Dog**

- All relevant tissues. no withdrawal period  
Not applicable to dogs.

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QN02AX02

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Belgium

---

**Package description:**

Cardboard box of 1 PVC/PE/PVDC-aluminium blister, containing 10 tablets.  
Cardboard box of 2 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 3 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 4 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 5 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 6 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 7 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 8 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 9 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 10 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 12 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.  
Cardboard box of 25 PVC/PE/PVDC-aluminium blisters, containing 10 tablets each.

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Hybrid application - change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

---

**Marketing authorisation holder:**

Alfasan Nederland B.V.

---

**Marketing authorisation date:**

26/07/2024

---

**Manufacturing sites for batch release:**

Lelypharma B.V.

---

**Responsible authority:**

Federal Agency For Medicines And Health Products

---

**Authorisation number:**

BE-V662981

---

**Date of authorisation status change:**

26/07/2024

---

**Reference member state:**

Netherlands

---

**Procedure number:**

NL/V/0387/003

---

**Concerned member states:**

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland  
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania  
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain  
Sweden United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

### Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

### Labelling

This document does not exist in this language (English). You can find it in another language below.

### Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

### Combined File of all Documents